Dihydroartemisinin: A Promising Therapeutic Agent Against the Hepatitis-to-Hepatocellular Carcinoma Cascade
Tingyao Wang, Wei Jiang, Jiqiang Li, Jia Ma, Yuanhao Zhang, Jijun Zheng, Jie Chen, Yueqiang Wen, Xiao Ma, Jinhao Zeng · 2025
Read Dihydroartemisinin: A Promising Therapeutic Agent Against the Hepatitis-to-Hepatocellular Carcinoma Cascade by Tingyao Wang, Wei Jiang, Jiqiang Li, Jia Ma, Yuanhao Zhang, Jijun Zheng, Jie Chen, Yueqiang Wen, Xiao Ma, Jinhao Zeng (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12716146.txt.
Description
Tingyao Wang and nine co-authors review a drug called dihydroartemisinin in a paper from twenty twenty-five. The drug is known for use against malaria. The review asks if it can also slow the long path from hepatitis to liver scarring and then to liver cancer.
The authors sum up lab and animal work on how the drug acts at each stage. It calms swelling signals, slows scar forming cells in the liver, and affects fat stores and cell death paths. Two key signal paths come up again and again in the evidence. The review presents the drug as a hopeful option, while the proof stays early and mostly preclinical.
Catalog record
| CREATOR | Tingyao Wang, Wei Jiang, Jiqiang Li, Jia Ma, Yuanhao Zhang, Jijun Zheng, Jie Chen, Yueqiang Wen, Xiao Ma, Jinhao Zeng |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 45 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |